/
We are a growth oriented and diversified next generation biotech, genomics and consumer products company company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. We offer whole genome sequencing and related services through our wholly-owned subsidiary, Nebula Genomics, Inc. ( Nebula ) and DNA Complete, Inc. ("DNA Complete").
$0.12
$0.00 (-0.17%)
Price from 41 days ago
The business is unprofitable at the operating level (-415.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 35.8% YoY. The question is whether this is cyclical or a structural shift.
ROIC dropped from -72.92% to -104.66%, capital efficiency is deteriorating. Negative free cash flow of -$8M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4M
▼ -35.8% YoY
Net Income (TTM)
-$15M
▲ +72.4% YoY
Op. Margin
-415.35%
▲ +155.2pp YoY
ROIC
-104.66%
▼ -31.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▲ +54.8% YoY
Op. Cash Flow (TTM)
-$8M
▲ +52.4% YoY
Net Debt
$3M
Cash & Equiv.
$90K
5Y CAGR: -21.4%
Continue Research